The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2020 | NICE rejection of osimertinib: what does this mean for EGFR+ NSCLC in the UK?
The National Institute for Health and Care Excellence (NICE) in the UK has rejected osimetinib for the treatment of EGFR+ non-small cell lung cancer (NSCLC). Here, Riyaz Shah, FRCP, PhD, The Royal Marsden Hospital, London, UK, discusses this decision and what in means for the treatment of this group in the UK. This interview took place at the 18th British Thoracic Oncology Group (BTOG) 2020 congress held in Dublin, UK.
